Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894212 | 0.85 | SRC (0.66) | PDGFRBPDGFRAKDRFGFR2SRC | |
| SCHEMBL7481439 | 0.84 | SRC (0.60) | PDGFRBPDGFRAKDRFGFR2EGFR | |
| SCHEMBL168048 | 0.83 | PDGFRB (0.79) | PDGFRBPDGFRAKDRFGFR2EGFR | |
| SCHEMBL3795538 | 0.82 | PDGFRB (0.65) | PDGFRBPDGFRAKDRFGFR2EGFR | |
| SCHEMBL4400367 | 0.82 | PDGFRB (0.72) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL30574469 | 0.82 | PDGFRB (0.60) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL4482829 | 0.82 | PDGFRB (0.60) | PDGFRBPDGFRAKDRFGFR2EGFR | |
| SCHEMBL29079702 | 0.82 | PDGFRB (0.60) | PDGFRBPDGFRAFGFR2EGFRSRC | |
| SCHEMBL4481865 | 0.82 | SRC (0.60) | PDGFRBPDGFRAKDRFGFR2EGFR | |
| SCHEMBL4365396 | 0.81 | PDGFRB (0.76) | PDGFRBPDGFRAKDRFGFR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598258-B2 | N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1535910-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | CSF3R, CSF1R, MSR1 | PDGFRB 123/4885PDGFRA 137/4885KDR 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.